Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Pfizer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

4Q Revenues: $13.6 billion (-9%)

4Q Earnings: $2.7 billion (-3%)

FY Revenues: $51.3 billion (-2%)

FY Earnings: $8.1 billion (-29%)

Comments: Human Health revenue declined 4% for the year due to U.S. generic competition for certain key medicines, uncertainty related to Celebrex, and the suspension of Bextra sales. Celebrex sales were down 53% to $472 million for the quarter. Lipitor sales were up 3% to $3.4 billion for the quarter, and up 12% to $12.2 billion for the year. Norvasc sales were down 1% to $1.2 billion for the quarter and sales for the year were up 5% to $4.7 billion. Caduet sales reached $65 million for the quarter, up from $15 million 4Q2004. The company launched Lyrica, an anti-epileptic drug, in the U.S. in September 2005.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters